Trials / Completed
CompletedNCT03636750
A Study of Injection HB002.1T in Subjects With Solid Tumor
A Phase 1, Safety, Tolerability and Pharmacokinetic Profile Study of Intravenous Injections of HB002.1T (a Vascular Endothelial Growth Factor Receptor Decoy) in Subjects With Solid Tumor
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Huabo Biopharm Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of HB002.1T, a human immunoglobulin Fc fusion protein containing domain 2 and flanking sequence of vascular endothelial growth factor (VEGF) receptor-1 in subjects with solid tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HB002.1T | HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy |
Timeline
- Start date
- 2018-06-28
- Primary completion
- 2020-02-20
- Completion
- 2020-03-21
- First posted
- 2018-08-17
- Last updated
- 2021-07-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03636750. Inclusion in this directory is not an endorsement.